Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Tarih
2017
Yazar
Hida, Toyoaki
Rittmeyer, Achim
Barlesi, Fabrice
Waterkamp, Daniel
Park, Keunchil
Ciardiello, Fortunato
von Pawel, Joachim
Gadgeel, Shirish M.
Kowalski, Dariusz M.
Dols, Manuel Cobo
Cortinovis, Diego L.
Leach, Joseph
Polikoff, Jonathan
Barrios, Carlos
Kabbinavar, Fairooz
Frontera, Osvaldo Aren
De Marinis, Filippo
Lee, Jong-Seok
Ballinger, Marcus
Kowanetz, Marcin
He, Pei
Chen, Daniel S.
Sandler, Alan
Gandara, David R.
Turna, Hande
Üst veri
Tüm öğe kaydını göster
Özet
Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.
Bağlantı
http://hdl.handle.net/20.500.12627/129840
https://doi.org/10.1016/s0140-6736(16)32517-x
Koleksiyonlar